NasdaqGS - Nasdaq Real Time Price USD

Achilles Therapeutics plc (ACHL)

Compare
0.9889 +0.0095 (+0.99%)
As of 10:03 AM EDT. Market Open.
Loading Chart for ACHL
DELL
  • Previous Close 0.9794
  • Open 0.9525
  • Bid 0.9241 x 100
  • Ask 1.0400 x 100
  • Day's Range 0.9525 - 0.9889
  • 52 Week Range 0.6300 - 1.7600
  • Volume 6,629
  • Avg. Volume 636,037
  • Market Cap (intraday) 42.23M
  • Beta (5Y Monthly) 1.35
  • PE Ratio (TTM) --
  • EPS (TTM) -1.5900
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.83

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

www.achillestx.com

204

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ACHL

View More

Performance Overview: ACHL

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ACHL
11.24%
MSCI WORLD
17.61%

1-Year Return

ACHL
9.39%
MSCI WORLD
0.00%

3-Year Return

ACHL
87.01%
MSCI WORLD
19.87%

5-Year Return

ACHL
94.51%
MSCI WORLD
32.57%

Compare To: ACHL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ACHL

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    42.06M

  • Enterprise Value

    -48.58M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.35

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.82%

  • Return on Equity (ttm)

    -44.22%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -63.97M

  • Diluted EPS (ttm)

    -1.5900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    95.11M

  • Total Debt/Equity (mrq)

    3.86%

  • Levered Free Cash Flow (ttm)

    -30.14M

Research Analysis: ACHL

View More

Company Insights: ACHL

Research Reports: ACHL

View More

People Also Watch